For best experience please turn on javascript and use a modern browser!
You are using a browser that is no longer supported by Microsoft. Please upgrade your browser. The site may not present itself correctly if you continue browsing.

Acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) are myeloid malignancies with a poor prognosis. Allogenic hematopoietic stem-cell transplantation (HSCT) is often used to treat these conditions, to induce a graft versus leukemia immune response. However, this is a high-risk therapy with many complications. Marijn Gillissen studies the role of B cells in GvL immune responses, with the aim of increasing our understanding of these immune responses and developing less harmful, more effective therapies.

Event details of Using immune responses to treat Leukemia
Date 12 January 2018
Time 10:00 -11:00
Location Agnietenkapel
Room Location

M.A. Gillissen: Allogeneic Hematopoietic Stem Cell Transplantation as Immunotherapy: B Lymphocytes versus Leukemia.

Supervisor

Prof. H. Spits

Co-supervisor

Dr M.D. Hazenberg

Agnietenkapel

Room Location

Oudezijds Voorburgwal 229 - 231
1012 EZ Amsterdam

Entrance

This event is open to the public.